Skip to main content

Table 1 Patient characteristics of the clinical trials reviewed

From: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

Study

N

F/M

Age (Mean)

Histology (N)

TNM Stage (N)

Quality of Life

Invention Group (N)

Group 1 (N)

Group 2 (N)

End point

Wang JW 2005[11]

486

140/346

18-75

SCC (129) LAC (165) Others (28)

IIIA (51) IIIB (81) IV (185)

ECGO

NPE versus NP + placebo

322

164

RR, DCR, TTP, SI, AEs

Yang L 2005[12]

87

28/59

37-76

SCC (34) LAC (50) Others (3)

III (32) IV (55)

ECGO

NPE versus NP

57

33

RR, DCR, SI, AEs

Cai L 2007[13]

71

25/46

NA

SCC (27) LAC (32) Others (12)

IIIA (9) IIIB (33) IV (29)

KPS

NPE versus NP

39

32

RR, DCR, AEs

Mu HY 2009[14]

62

22/40

42-75

SCC (28) LAC (34)

IIIB (28) IV (34)

KPS

NPE versus NP (16) TPE versus TP (6) PPE versus PP (8)

32

30

RR, DCR, SI, AEs

Liao HY 2009[15]

85

32/53

36-72

SCC (36) LAC (49)

IIIB (32) IV (53)

KPS

GPE versus GP

30

55

RR, DCR, OYS, AEs

Zang T 2009[16]

104

36/68

42-68

NA

IIIB (58) IV (46)

ECGO

GPE versus GP

48

56

RR, DCR, SI, AEs

Liu J 2009[17]

62

17/45

29-68

SCC (38) LAC (24)

III (37) IV (25)

KPS

NPE + RT versus NP + RT

31

31

RR, DCR, TTP, AEs

Ma JB 2009[18]

46

11/35

38-73

SCC (31) LAC (15)

IIIA (26) IIIB (20)

ECGO

NPE + RT versus NP + RT

23

23

RR, DCR, TTP, AEs

Shi GY 2009[19]

462

162/300

20-74

SCC (190) LAC (252) Others (20)

IIIA (92) IIIB (144) IV (226)

ECGO

GPE versus GP

308

154

RR, DCR, TTP, SI, AEs

Han BH 2011[20]

122

35/87

28-78

SCC (37) LAC (78) Others (7)

IIIB (43) IV (79)

ECGO

TCE versus TC + placebo

61

61

RR, DCR, AEs

Zhao X 2011[21]

69

23/46

35-73

SCC (34) LAC (25) Others(10)

IIIB (11) IV (58)

ECGO

GPE versus GP

33

36

RR, DCR, AEs

Hu HT 2011[22]

89

21/68

41-70

SCLC (89)

NA

KPS

TPE versus TP

45

44

RR, DCR, AEs

Wen F 2011[23]

84

27/57

54-75

SCC (36) LAC (44) Others (4)

NA

KPS

NPE versus NP

43

41

RR, DCR, AEs

Zhang H 2011[24]

56

15/41

36-75

SCC (18) LAC (33) Others (5)

IIIB (32) IV (25)

KPS

NPE versus NP (2) GPE versus GP (15) TPE versus TP (11)

28

28

RR, DCR, TTP, OYS, AEs

Chen Q 2011[25]

68

27/41

42-75

SCC (20) LAC (44) Others (4)

IIIA (15) IIIB (41) IV (12)

NA

GPE versus GP

33

35

RR, DCR, SI

  1. AEs , adverse effects; DCR, disease control rate; ECGO, eastern cooperative oncology group; F/M, female/male; GP, gemcitabine + cisplatin; GPE, gemcitabine + cisplatin + Endostar; Group 1, Endostar combined with PBDC; Group 2, PBDC alone; KPS, Karnofsky physical status score; LAC, lung adenocarcinoma; N, number of patients; NA, not available; NP, vinorelbine + cisplatin; NPE, vinorelbine + cisplatin + Endostar; OYS, one-year survival rate; PP, paclitaxel + cisplatin; PPE, paclitaxel + cisplatin + Endostar; RR, response rate; RT, radiotherapy; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer; SI, symptom improvement; TC, paclitaxel + carboplatin; TCE, paclitaxel + carboplatin + Endostar; TP, docetaxel + cisplatin; TP, TPE, docetaxel + cisplatin + Endostar; TTP, time to progression;